blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3351552

EP3351552 - 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT [Right-click to bookmark this link]
Former [2018/30]2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
[2020/49]
StatusNo opposition filed within time limit
Status updated on  25.03.2022
Database last updated on 28.05.2024
FormerThe patent has been granted
Status updated on  16.04.2021
FormerGrant of patent is intended
Status updated on  30.11.2020
FormerRequest for examination was made
Status updated on  22.06.2018
Most recent event   Tooltip03.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 05.06.2024 [2024/23]
Applicant(s)For all designated states
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
[2018/30]
Inventor(s)01 / CLARKE, Michael O' Neil Hanrahan
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
 [2018/30]
Representative(s)Fairbairn, Angus Chisholm
Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[2021/20]
Former [2018/30]Fairbairn, Angus Chisholm
Marks & Clerk LLP
90 Long Acre
London WC2E 9RA / GB
Application number, filing date18155061.711.03.2013
[2018/30]
Priority number, dateUS201261610411P13.03.2012         Original published format: US 201261610411 P
[2018/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3351552
Date:25.07.2018
Language:EN
[2018/30]
Type: B1 Patent specification 
No.:EP3351552
Date:19.05.2021
Language:EN
[2021/20]
Search report(s)(Supplementary) European search report - dispatched on:EP21.06.2018
ClassificationIPC:C07H19/23, A61K31/706, A61P31/16, A61P31/00, A61P31/14, A61P43/00
[2020/49]
CPC:
C07H19/23 (EP,US); A61K31/706 (EP,US); A61K45/06 (US);
A61P31/00 (EP); A61P31/14 (EP); A61P31/16 (EP);
A61P43/00 (EP); C07D487/04 (EP); C07H19/12 (US);
A61M15/00 (EP); A61M2202/30 (EP) (-)
Former IPC [2018/30]C07H19/23, A61K31/706, A61P31/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/30]
TitleGerman:2'-SUBSTITUIERTE CARBA-NUKLEOSID-ANALOGA ZUR ANTIVIRALEN BEHANDLUNG[2018/30]
English:2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT[2020/49]
French:ANALOGUES DE CARBA-NUCLÉOSIDE 2'-SUBSTITUÉS POUR TRAITEMENT ANTIVIRAL[2018/30]
Former [2018/30]2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
Examination procedure05.02.2018Examination requested  [2018/30]
05.02.2018Date on which the examining division has become responsible
02.01.2019Amendment by applicant (claims and/or description)
01.12.2020Communication of intention to grant the patent
09.04.2021Fee for grant paid
09.04.2021Fee for publishing/printing paid
09.04.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP13712043.2  / EP2834258
EP16203290.8  / EP3210993
Divisional application(s)EP21168626.6  / EP3932931
Opposition(s)22.02.2022No opposition filed within time limit [2022/17]
Fees paidRenewal fee
05.02.2018Renewal fee patent year 03
05.02.2018Renewal fee patent year 04
05.02.2018Renewal fee patent year 05
27.03.2018Renewal fee patent year 06
27.03.2019Renewal fee patent year 07
27.03.2020Renewal fee patent year 08
12.03.2021Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU11.03.2013
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
MK19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
[2024/23]
Former [2024/20]HU11.03.2013
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2024/18]HU11.03.2013
AL19.05.2021
AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/47]AL19.05.2021
AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/29]AL19.05.2021
AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/26]AL19.05.2021
AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/23]AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/10]AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
IS22.12.2021
Former [2022/09]AT19.05.2021
CZ19.05.2021
DK19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/08]AT19.05.2021
CZ19.05.2021
DK19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RS19.05.2021
SE19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/07]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RS19.05.2021
SE19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/04]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RS19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/52]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
PL19.05.2021
RS19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/51]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RS19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/50]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
Former [2021/49]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
Former [2021/47]AT19.05.2021
FI19.05.2021
LT19.05.2021
BG19.08.2021
Former [2021/46]AT19.05.2021
FI19.05.2021
LT19.05.2021
Documents cited:Search[A]WO0232920  (PHARMASSET LTD [US], et al) [A] 1-20 * Claims, examples and pages 1-8 *;
 [AD]WO2009132123  (GILEAD SCIENCES INC [US], et al) [AD] 1-20 * Claims and examples *;
 [AD]WO2009132135  (GILEAD SCIENCES INC [US], et al) [AD] 1-20* Claims and examples *
by applicantUS3361306
 US3565070
 US3906950
 US4013075
 US4069819
 US4668218
 US4667668
 US4805811
 US4816570
 US4955371
 US4968788
 US4995385
 US5261538
 US5388572
 US5458135
 US5522385
 US5544647
 US5622163
 US5663159
 US5740794
 US5775320
 US5785049
 US5792756
 US6116234
 WO0056734
 WO2008089105
 WO2008141079
 WO2009132123
 WO2009132135
 WO2010002877
    - MEMOLI et al., Drug Discovery Today, (20080000), vol. 13, pages 590 - 595
    - HEDLUND et al., Viruses, (20100000), vol. 2, pages 1766 - 1781
    - Carbohydrate Research, (20010000), vol. 331, no. 1, pages 77 - 82
    - Nucleosides & Nucleotides, (19960000), vol. 15, no. 1-3, pages 793 - 807
    - Tetrahedron Letters, (19940000), vol. 35, no. 30, pages 5339 - 42
    - Heterocycles, (19920000), vol. 34, no. 3, pages 569 - 74
    - J. Chem. Soc. Perkin Trans., (19850000), vol. 1, no. 3, pages 621 - 30
    - J. Chem. Soc. Perkin Trans., (19840000), vol. 1, no. 2, pages 229 - 38
    - Organic Letters, (20010000), vol. 3, no. 6, pages 839 - 842
    - J. Chem. Soc. Perkin Trans., (19990000), vol. 1, no. 20, pages 2929 - 2936
    - J. Med. Chem., (19860000), vol. 29, no. 11, pages 2231 - 5
    - The Chemistry of Heterocyclic Compounds, A Series of Monographs, John Wiley & Sons, (19500000), vol. 13, 14,
    - J. Am. Chem. Soc., (19600000), vol. 82, page 5566
    - "Design and Application of Prodrugs", BUNDGAARD, HANS, Textbook of Drug Design and Development, Harwood Academic Publishers, (19910000), pages 113 - 191
    - FARQUHAR et al., J. Pharm. Sci., (19830000), vol. 72, page 324
    - DENYER, J. Aerosol Medicine Pulmonary Drug Delivery, (20100000), vol. 23, no. 1, pages S1 - S10
    - CARRYER, Journal of Allergy, (19500000), vol. 21, pages 282 - 287
    - MORRIS, J. Allergy Clin. Immunol., (19850000), vol. 75, no. 1, pages 1 - 13
    - KUZIK, J. Pediatrics, (20070000), page 266
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.